Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Juan Berlanga"'
Autor:
Queipo de Llano Mp, Dolors Colomer, Andreu Llorente, Jordi Sierra, Luz Muñoz, José María Raya Sánchez, Josep F. Nomdedeu, Josep-Maria Ribera, Salut Brunet, Juan Berlanga, C. Fernández, JP Torres, Ramon Guardia, Neus Villamor
Publikováno v:
Leukemia. 17:76-82
The MLL gene, located at 11q23 band, is frequently disrupted by different chromosomal rearrangements that occur in a variety of hematological malignancies. MLL rearrangements are associated with distinct clinical features and a poor prognosis. The ai
Autor:
Jordi Esteve, Cetlam, Salut Brunet, Granada Perea, Alfons Navarro, Emili Montserrat, Alvaro Urbano-Ispizua, Javier Bueno, Josep M. Ribera, Andreu Llorente, Jordi Sierra, Juan Berlanga, Josep F. Nomdedeu, Ramon Guardia, Mar Tormo, Rosa Artells, Miquel Granell, Mariano Monzo, Pio Torres
Publikováno v:
Blood. 107(12)
Current prognostic factors for acute myeloblastic leukemia (AML) are not sufficient to accurately predict the group of patients in the intermediate-risk category who will successfully respond to treatment. Distinct patterns of inherited functional ge
Autor:
Josep F. Nomdedeu, Granada Perea, Alicia Domingo, Lourdes Florensa, Isabel Badell, J. Bargay, C. Palacios, Jordi Sierra, Pio Torres, Jordi Juncà, Salut Brunet, Anna Aventin, Neus Villamor, M. Paz Queipo De Llano, Adriana Lasa, Llorens Font, Andreu Llorente, C. Fernández, Josep Martí, Juan Berlanga, M. Gallart, Pilar Vivancos, Mar Tormo
Publikováno v:
Leukemia. 20(1)
Most patients with acute myeloid leukemia (AML) and t(8;21) or inv(16) have a good prognosis with current anthracycline- and cytarabine-based protocols. Tandem analysis with flow cytometry (FC) and real-time RT-PCR (RQ-PCR) was applied to 55 patients
Autor:
Javier Bueno, Ll. Font, Mar Tormo, Granada Perea, Jordi Esteve, M. Gallart, Josep-Maria Ribera, Andreu Llorente, Lourdes Florensa, Josep Martí, Alicia Domingo, Pio Torres, Jordi Juncà, Juan Berlanga, Salut Brunet, Pilar Vivancos, J. Bargay, C. Palacios, M.P. Queipo de Llano, Jordi Sierra, J. Nomdedeu, Neus Villamor, C. Fernández
Publikováno v:
Publons
Background and objectives: A consecutive series of acute myeloid leukemias (AML) patients was analyzed in conditions which reduce the inter-assay variations (the same flow cytometer, the same observers and the same panel of monoclonal antibodies) in
Autor:
D Caballero, C Sanz-Rodriguez, Antoni Torres, D Serrano, Jordi Sierra, Coral Martin, Enric Carreras, R de la Cámara, I Espigado, Salut Brunet, David Gallardo, Antonio M. Jimenez, Juan Carlos Vallejo, Juan Berlanga, Guillermo Sanz
Publikováno v:
Leukemia. 18(5)
Predicting survival for myeloid leukemia after HLA-identical sibling donor allogeneic stem cell transplantation
Autor:
Jordi Esteve, Juan Besalduch, Jorge Sierra, J. Bargay, Salut Brunet, Josep Martí, M.P. Queipo de Llano, Janeth Sánchez, David Valcárcel, Javier Bueno, Juan Berlanga, J. Guardia, Pilar Vivancos, Josep-Maria Ribera, Llorens Font, Andreu Llorente, Pio Torres, Mar Tormo, José-María Moraleda, I Sánchez-Ortega, Emili Montserrat, D. Hernández, Carmen Pedro
Publikováno v:
Blood. 108:1972-1972
Complications during induction chemotherapy (CT) for AML cause mortality in 5–20% of cases. It is relevant to define the risk of early death in this setting. In patients with a high probability of dying due to toxicity, the intensification of the s
Autor:
Jordi Esteve, Mar Tormo, Ramon Guardia, Javier Bueno, Feliu E, Jorge Sierra, Granada Perea, Pio Torres, Joan Bargay, Carmen Pedro, Pilar Vivancos, Emili Montserrat, Andreu Llorente, Joan Besalduch, Josep M. Sanchez, Maria Paz Queipo De Llano, Salut Brunet, Josep M. Ribera, Josep Martí, Juan Berlanga, José M. Moraleda
Publikováno v:
Blood. 106:1855-1855
We analyzed the complete remission (CR) rate and toxicity in patients (pts) with “de novo” AML enrolled in an intensive CT protocol including induction and intensification CT concurrently with G-CSF. Between December-2003 and April-2005 167 adult
Autor:
Llorens Font, Jordi Esteve, Ramon Guardia, Josep Martí, Andreu Llorente, Salut Brunet, Juan-Maria Sanchez, Juan Berlanga, Mar Tormo, Javier Bueno, José-María Moraleda, Pilar Vivancos, Jorge Sierra, Alfons Navarro, Alvaro Urbano-Ispizua, Maria-Jesus Peñarubia, Granada Perea, Juan Besalduch, Josep-Maria Ribera, Emili Montserrat, Maria-Paz Queipo de Llano, Mariano Monzo, Josep F. Nomdedeu, Carmen Pedro, Pio Torres
Publikováno v:
Blood. 104:398-398
In this study we tested whether distinct patterns of functional genomic polymorphisms in genes involved in drug metabolic pathways (GSTT1, SULT1C2, CD-EX, TOP2A, SXR-1, SXR-2), DNA repair (XPD, XPA, XPG, ERCC1), angiogenesis (VEGF-1, VEGF-2), and mul
Autor:
Alicia Domingo, Neus Villamor, Adriana Lasa, Joan Bargay, Carlos Palacios, Anna Aventin, Josep F. Nomdedeu, Cristalina Fernandez, Jorge Sierra, Pilar Vivancos, Granada Perea, Miquel Guallart, Lourdes Florensa, Mar Tormo, Maria Paz Queipo De Llano, Salut Brunet, Andreu Llorente, Pio Torres, Jordi Juncà, Llorens Font, Josep Martí, Juan Berlanga
Publikováno v:
Blood. 104:2989-2989
Objectives: To analyze MRD in 65 patients (pts) with good prognosis AML: 30 t(8;21) and 35 inv(16), using both FC and RT-PCR, and to investigate the prognostic value of MRD in the pts outcome. Methods: MRD was monitored in CR pts (n=55) by FC in 101